Table 4.

Univariate Cox regression analysis of factors associated with survival

Factors	Number of deaths (%)	Hazard ratio	95%CI	P-value
Gender
• Female	113 (72.9)	1.0	–	0.36
• Male	115 (71)	0.89	0.68,1.15
Age
• Age < 60	86 (68.3)	1.0	–	0.96
• Age ≥ 60	142 (74.4)	1.01	0.77,1.32
Marital status
• Married	153 (69.6)	1.0	–	0.62
• Divorced	19 (82.6)	1.30	0.81,2.10
• Widowed	33 (76.7)	1.03	0.71,1.51
• Single	23 (74.2)	1.23	0.80,1.91
Type of malignancy
• Head and neck cancer	26 (60.5)	1.0	–	0.26
• Breast cancer	16 (72.7)	1.40	0.75,2.62
• Primary lung cancer	41 (71.9)	1.09	0.66,1.78
• Gastrointestinal cancer	99 (78)	1.51	0.98,2.34
• Genitourinary cancer	24 (70.6)	1.07	0.62,1.87
• Others	22 (67.7)	1.15	0.65,2.03
Metastases
Evidence of metastases at consultation	204 (72.3)	1.0	–	0.33
No metastases	24 (68.5)	0.81	0.53,1.24
PPS (%)
• ≤ 30	113 (86.9)	1.0	–	<0.01
• 40–60	73 (71.6)	0.27	0.20,0.38
• ≥ 70	30 (46.2)	0.11	0.07,0.16
Type of service
• No home visit	151 (68.6)	1.0	–	0.04
• Home visit	77 (79.4)	0.75	0.57,0.99
• No palliative care clinic visit	154 (80.6)	1.0	–	<0.01
• Palliative care clinic visit	74 (58.7)	0.32	0.24,0.43
• No hospital admission	81 (64.3)	1.0	–	<0.01
• Having hospital admission	147 (77)	2.03	1.54,2.67
Concurrent treatment
• No chemotherapy	195 (76.5)	1.0	–	<0.01
• Receiving chemotherapy	33 (53.2)	0.32	0.22,0.46
• No radiotherapy	198 (73.9)	1.0	–	<0.01
• Receiving radiotherapy	30 (61.2)	0.53	0.36,0.78
• No surgery	220 (72.4)	1.0	–	0.12
• Receiving surgery	8 (61.5)	0.60	0.29,1.20
Charlson comorbidity index (CCI)
• ≤ 3	132 (67.7)	1.0	–	0.26
• > 3	95 (78.5)	1.16	0.89,1.52
Oral morphine equivalent (mg/day)
• ≤ 30 mg/day	170 (69.7)	–	–	0.52
• > 30 mg/day	58 (79.5)	1.14	0.77,1.69